Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tozasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 11/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 11/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 3/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | MUSK | O15146 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tozasertib SCHEMBL29386202 | 0.95 | AURKA (0.90) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL13004578 | 0.93 | AURKA (0.87) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL18656672 | 0.92 | AURKA (0.85) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL19826565 | 0.92 | AURKA (0.85) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL18651118 | 0.92 | AURKA (0.85) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL18656590 | 0.91 | AURKB (0.84) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL18656675 | 0.91 | AURKA (0.84) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL13004582 | 0.90 | AURKB (0.82) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL29504155 | 0.89 | AURKB (1.00) | AURKAAURKBPLK4RIPK1AURKC | |
| SCHEMBL12430853 | 0.89 | AURKB (1.00) | AURKAAURKBPLK4RIPK1AURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2974 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076941-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | UNIV GEORGETOWN (US) | 2026-03-19 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2788504-B1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY OLOMOUC (CZ) | 2016-08-17 | — | — | EP | claimed |
| US-20140336073-A1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2014-11-13 | — | — | US | claimed |
| EP-2788504-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | Palacky University, Olomouc (CZ) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083098-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2013-06-13 | — | — | WO | claimed |
| EP-2602330-A1 | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance | Palacky University, Olomouc (CZ) | 2013-06-12 | — | — | EP | claimed |